Drug name - Jentadueto Xr
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7407955 | BOEHRINGER INGELHEIM | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
May, 2025
(2 years from now) | |
| CN102964347B | BOEHRINGER INGELHEIM | 8-[3-Amino-Piperidin-1-Yl]-Xanthines, Preparation Method Thereof And Application Thereof As Medicament |
Aug, 2023
(10 months from now) | |
| CN101503408A | BOEHRINGER INGELHEIM | 8-(3-Amino-Piperidin-1-Yl)-Xanthines Compound |
Aug, 2023
(10 months from now) | |
| CN101503408B | BOEHRINGER INGELHEIM | 8 - (3 - - Piperidine-1 - - Yl] - Xanthine Compounds |
Aug, 2023
(10 months from now) | |
| CN101503409A | BOEHRINGER INGELHEIM | 8-(3-Amino-Piperidin-1-Yl)-Xanthines, The Production Thereof And The Use Of The Same As Medicaments |
Aug, 2023
(10 months from now) | |
| CN100522962C | BOEHRINGER INGELHEIM | 8 - [3-Amino-Piperidin-1-Yl] - Xanthine, Its Preparation Method And Purpose As Medicine Preparation |
Aug, 2023
(10 months from now) | |
| CN101503409B | BOEHRINGER INGELHEIM | 8 - [3-Amino-Piperidin-L-Yl] - Xanthines, Processes For Their Preparation And Their Use As Pharmaceutical Preparations |
Aug, 2023
(10 months from now) | |
| CN105001222B | BOEHRINGER INGELHEIM | 8 - (3-Amino-Piperidin-1-Yl] - Xanthine, Its Preparation Method And Purpose As Medicine Preparation |
Aug, 2023
(10 months from now) | |
| CN102964347A | BOEHRINGER INGELHEIM | 8 - (3 - - Piperidine-1 - - Yl] - Xanthine Compound, Preparation Method And Use Thereof As Pharmaceutical Preparation |
Aug, 2023
(10 months from now) | |
| CN105001222A | BOEHRINGER INGELHEIM | 8-[3-Amino-Piperidin-1-Yl]-Xanthines, Preparation Method Thereof And Application Thereof As Medicament |
Aug, 2023
(10 months from now) | |
| CN1675212A | BOEHRINGER INGELHEIM | 8 - (3-Amino-Piperidin-1-Yl] - Xanthine, Its Preparation Method And Its Purpose As A Pharmaceutical Preparation |
Aug, 2023
(10 months from now) | |
| IN243301B | BOEHRINGER INGELHEIM | 8-(3-Aminopiperidin-1-Yl)-Xanthine Compounds |
Aug, 2023
(10 months from now) | |
| IN200500567P1 | BOEHRINGER INGELHEIM | 8-(3-Aminopiperidin-1-Yl)-Xanthine Compounds |
Aug, 2023
(10 months from now) | |
| EP1532149B9 | BOEHRINGER INGELHEIM | 8-[3-Amino-Piperidin-1-Yl]-Xanthines, The Production Thereof And The Use Of The Same As Medicaments |
Aug, 2026
(3 years from now) | |
| EP1532149B1 | BOEHRINGER INGELHEIM | 8-[3-Amino-Piperidin-1-Yl]-Xanthines, The Production Thereof And The Use Of The Same As Medicaments |
Aug, 2026
(3 years from now) | |
| EP1532149A2 | BOEHRINGER INGELHEIM | 8-[3-Amino-Piperidin-1-Yl]-Xanthines, The Production Thereof And The Use Of The Same As Medicaments |
Aug, 2026
(3 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8119648 | BOEHRINGER INGELHEIM | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
Aug, 2023
(10 months from now) | |
| US8178541 | BOEHRINGER INGELHEIM | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
Aug, 2023
(10 months from now) | |
| US8883805 | BOEHRINGER INGELHEIM | Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines |
Nov, 2025
(3 years from now) | |
| US8673927 | BOEHRINGER INGELHEIM | Uses of DPP-IV inhibitors |
May, 2027
(4 years from now) | |
| US9173859 | BOEHRINGER INGELHEIM | Uses of DPP IV inhibitors |
May, 2027
(4 years from now) | |
| US10022379 | BOEHRINGER INGELHEIM | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
Apr, 2029
(6 years from now) | |
| US9415016 | BOEHRINGER INGELHEIM | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
Apr, 2029
(6 years from now) | |
| US9155705 | BOEHRINGER INGELHEIM | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
May, 2030
(7 years from now) | |
| US9555001 | BOEHRINGER INGELHEIM | Pharmaceutical composition and uses thereof |
Mar, 2033
(10 years from now) | |
Drugs and Companies using LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient
Treatment: Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor; Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor in combination with metformin and, optionally, a sulfonylurea; Method of treating type 2 diabetes mellitus by administering linagliptin in combination with metformin; Use of a pharmaceutical composition comprising linagliptin, metformin and a basic amino acid to treat type 2 diabetes mellitus; Method of treating type 2 diabetes in patients with insufficient glycemic control despite therapy with one or more conventional antihyperglycemic agents by administering linagliptin in combination with metformin; method of treating type 2 diabetes in patients who have not been previously treated with an antihyperglycemic agent by administering linagliptin in combination with metformin
Dosage: TABLET, EXTENDED RELEASE;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 2.5MG;1GM | TABLET, EXTENDED RELEASE;ORAL | Prescription |
| 5MG;1GM | TABLET, EXTENDED RELEASE;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.